Literature DB >> 19883213

Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol.

Niravkumar R Patel1, Sophia Hatziantoniou, Aristidis Georgopoulos, Costas Demetzos, Vladimir P Torchilin, Volkmar Weissig, Gerard G M D'Souza.   

Abstract

Current efforts toward improving the effectiveness of drug therapy are increasingly relying on drug-targeting strategies to effectively deliver bioactive molecules to their molecular targets. Pharmaceutical nanocarriers represent a major tool toward this aim, and our efforts have been directed toward achieving nanocarrier-mediated subcellular delivery of drug molecules with mitochondria as the primary subcellular target. Meeting the need for specific subcellular delivery is essential to realizing the full potential of many poorly soluble anticancer drugs. In this article, we report that mitochondria-targeted liposomes significantly improve the apoptotic and cytotoxic action of sclareol, a poorly soluble potential anticancer drug. The results support the broad applicability of our nanocarrier-mediated subcellular targeting approach as a means to improve the effectiveness of certain anticancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19883213     DOI: 10.3109/08982100903347931

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  19 in total

1.  Multiple triphenylphosphonium cations as a platform for the delivery of a pro-apoptotic peptide.

Authors:  Netanel Kolevzon; Uriel Kuflik; Miriam Shmuel; Sandrine Benhamron; Israel Ringel; Eylon Yavin
Journal:  Pharm Res       Date:  2011-06-02       Impact factor: 4.200

Review 2.  Functionalized nanosystems for targeted mitochondrial delivery.

Authors:  Shelley A Durazo; Uday B Kompella
Journal:  Mitochondrion       Date:  2011-11-23       Impact factor: 4.160

3.  Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.

Authors:  Swati Biswas; Namita S Dodwadkar; Pranali P Deshpande; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-01-20       Impact factor: 9.776

Review 4.  From serendipity to mitochondria-targeted nanocarriers.

Authors:  Volkmar Weissig
Journal:  Pharm Res       Date:  2011-08-11       Impact factor: 4.200

5.  The utility of an isolated mitochondrial fraction in the preparation of liposomes for the specific delivery of bioactives to mitochondria in live mammalian cells.

Authors:  Mayura A Wagle; Laura E Martinville; Gerard G M D'Souza
Journal:  Pharm Res       Date:  2011-07-15       Impact factor: 4.200

6.  Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting.

Authors:  Jingchao Xi; Meng Li; Benxin Jing; Myunggi An; Chunsong Yu; Cameron B Pinnock; Yingxi Zhu; Mai T Lam; Haipeng Liu
Journal:  ACS Appl Mater Interfaces       Date:  2018-12-06       Impact factor: 9.229

Review 7.  Insight into nanoparticle cellular uptake and intracellular targeting.

Authors:  Basit Yameen; Won Il Choi; Cristian Vilos; Archana Swami; Jinjun Shi; Omid C Farokhzad
Journal:  J Control Release       Date:  2014-06-28       Impact factor: 9.776

8.  Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting.

Authors:  Swati Biswas; Namita S Dodwadkar; Rupa R Sawant; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2011-02-25       Impact factor: 5.121

9.  Imaging C-Fos Gene Expression in Burns Using Lipid Coated Spion Nanoparticles.

Authors:  Aristarchos Papagiannaros; Valeria Righi; George G Day; Laurence G Rahme; Philip K Liu; Alan J Fischman; Ronald G Tompkins; A Aria Tzika
Journal:  Adv J Mol Imaging       Date:  2012-10

Review 10.  Nanotechnology inspired tools for mitochondrial dysfunction related diseases.

Authors:  Ru Wen; Bhabatosh Banik; Rakesh K Pathak; Anil Kumar; Nagesh Kolishetti; Shanta Dhar
Journal:  Adv Drug Deliv Rev       Date:  2016-01-09       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.